Recommended Topic Related To:

Buphenyl

"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.

Dotarem is a gadolinium-based"...

Buphenyl

Warnings
Precautions

WARNINGS

Each BUPHENYL® (sodium phenylbutyrate tablets) Tablet contains 62 mg of sodium (9.2% w/w) (corresponding to 124 mg of sodium per gram of sodium phenylbutyrate [12.4% w/w]) and BUPHENYL (sodium phenylbutyrate tablets) Powder contains 11.7 grams of sodium per 100 grams of powder, corresponding to 125 mg of sodium per gram of sodium phenylbutyrate (12.4% w/w). BUPHENYL (sodium phenylbutyrate tablets) should be used with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states in which there is sodium retention with edema.

Because BUPHENYL (sodium phenylbutyrate tablets) is metabolized in the liver and kidney, and phenylacetylglutamine is primarily excreted by the kidney, use caution when administering the drug to patients with hepatic or renal insufficiency or inborn errors of beta oxidation. Probenecid is known to inhibit the renal transport of many organic compounds, including hippuric acid, and may affect renal excretion of the conjugated product of BUPHENYL (sodium phenylbutyrate tablets) as well as its metabolite.

Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels.

PRECAUTIONS

General

BUPHENYL® (sodium phenylbutyrate tablets) should not be administered to patients with known hypersensitivity to sodium phenylbutyrate or any component of this preparation.

There have been published reports of hyperammonemia being induced by haloperidol and by valproic acid.

Neurotoxicity of phenylacetate in animals

When given subcutaneously to rat pups, 190–474 mg/kg phenylacetate caused decreased proliferation and increased loss of neurons, and it reduced CNS myelin. Cerebral synapse maturation was retarded, and the number of functioning nerve terminals in the cerebrum was reduced, which resulted in impaired brain growth. Prenatal exposure of rat pups to phenylacetate produced lesions in layer 5 of the cortical pyramidal cells; dendritic spines were longer and thinner than normal and reduced in number.

Information for Patients

See the full text of the separate insert of PATIENT INFORMATION.

Laboratory Tests

Plasma levels of ammonia, arginine, branched-chain amino acids, and serum proteins should be maintained within normal limits, and plasma glutamine should be maintained at levels less than 1,000 Ámol/L. Serum drug levels of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine, should be monitored periodically.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity, and fertility studies of sodium phenylbutyrate have not been conducted.

Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with BUPHENYL® (sodium phenylbutyrate tablets) . It is also not known whether BUPHENYL (sodium phenylbutyrate tablets) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

BUPHENYL (sodium phenylbutyrate tablets) should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BUPHENYL® (sodium phenylbutyrate tablets) is administered to a nursing woman.

Pediatric Use

The use of tablets for neonates, infants and children to the weight of 20 kg is not recommended. (See DOSAGE AND ADMINISTRATION)

Last reviewed on RxList: 4/22/2009
This monograph has been modified to include the generic and brand name in many instances.

Warnings
Precautions
A A A

Buphenyl - User Reviews

Buphenyl User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Buphenyl sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.